Zydus Lifesciences revenue and financials
₹1,153.00Change from previous close: −0.56%Absolute change: −₹6.50
In the fiscal year ended March 2026, Zydus Lifesciences reported revenue of ₹267.2B (+18.37% year over year). Net income was ₹50.4B, a net margin of 18.9%.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +18.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net income growth
- +11.37%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- 18.9%
- FY to Mar 2025: 20.0%
Financial data
Amounts in millions of INR; per-share values in INR; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 |
|---|---|---|---|---|---|
| Operating cash flow | 21,166 | 67,811 | 31,963 | 26,888 | — |
| Depreciation and amortization | 14,080 | 9,158 | 7,641 | 7,227 | — |
| Capital expenditure | -26,715 | -16,937 | -9,066 | -10,309 | — |
| Investing cash flow | -82,961 | -83,578 | -14,752 | 15,350 | — |
| Financing cash flow | 58,069 | 19,953 | -17,788 | -44,004 | — |
| Dividends paid | -11,063 | -3,025 | -6,210 | -2,671 | — |
| Share repurchases | — | 0.0 | -7,250 | -8,632 | 0.0 |
| Debt issued | 70,710 | 0.0 | 0.0 | 1,552 | — |
| Debt repaid | -9,679 | 0.0 | -827 | -9,960 | — |
| Effect of exchange rates | 2,108 | -214 | -231 | 66.0 | — |
| Net change in cash | -3,726 | 4,186 | -577 | -1,766 | — |
| Free cash flow | -5,549 | 50,874 | 22,897 | 16,579 | — |